期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 29, 期 2, 页码 205-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2014.10.013
关键词
Bladder cancer; Urothelial carcinoma of the bladder; Staging; Diagnosis; Cystoscopy; Imaging; Screening; Biomarkers
资金
- Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women's Hospital
Bladder cancer (BCa) is a heterogeneous disease with a variable natural history. Most patients (70%) present with superficial tumors (stages Ta, T1, or carcinoma in situ). However, 3 out of 10 patients present with muscle-invasive disease (12-4) with a high risk of death from distant meta-stases. Moreover, roughly between 50% and 70% of superficial tumors do recur, and approximately 10% to 20% of them progress to muscle-invasive disease. However, BCa has a relatively low ratio of mortality versus incidence of new cases. In consequence, there is the danger of overdiagnosis and overtreatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据